NCT03310320View on ClinicalTrials.gov

Study to Determine if AZD0284 is Effective and Safe in Treating Plaque Psoriasis

PHASE1TerminatedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

November 29, 2017

Primary Completion Date

April 18, 2018

Study Completion Date

April 18, 2018

Conditions
Plaque Psoriasis Vulgaris
Interventions
DRUG

AZD0284 oral solution 2.5 mg/mL

AZD0284 oral solution 2.5 mg/mL, 100 mg twice daily for for 4 weeks

DRUG

Placebo

Placebo for AZD0284 oral solution, twice daily for 4 weeks

Trial Locations (4)

2400

Research Site, Copenhagen

2900

Research Site, Hellerup

5000

Research Site, Odense

8000

Research Site, Aarhus C

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY